Patient characteristics and outcomes
| Characteristics . | N (%) . |
|---|---|
| Total patients | 66 (100) |
| Age, median (range) (y) | 54.9 (23-59) |
| Gender | |
| Male | 37 (56) |
| Female | 29 (44) |
| AML subtype | |
| AML-MRC | 52 (79) |
| Morphology | 17 (26) |
| Cytogenetics | 11 (17) |
| Prior Dx MDS | 23 (35) |
| Prior Dx CMML | 1 (2) |
| Therapy-related AML | 14 (21) |
| Previous HMA treatment for MDS | |
| Yes | 16 (24) |
| No | 50 (76) |
| Baseline mutations of interest | |
| TP53 | 19 (30) |
| RUNX1 | 14 (22) |
| DNMT3A | 11 (17) |
| NRAS | 11 (17) |
| ASXL1 | 7 (11) |
| NPM1 | 7 (11) |
| FLT3 ITD | 5 (8) |
| IDH1 | 5 (8) |
| IDH2 | 3 (5) |
| Cytogenetics | |
| Complex | 30 (46) |
| Monosomal | 17 (26) |
| Normal | 10 (15) |
| Del 7 | 7 (11) |
| Trisomy 8 | 4 (16) |
| 17p | 3 (5) |
| Minus 5q | 2 (3) |
| Outcomes (out of 62 pts) | |
| CR | 19 (30.6) |
| CRi | 8 (12.9) |
| CR/CRi | 27 (43.5) |
| MLFS | 2 (3.2) |
| NR | 33 (53) |
| Mortality | |
| 30 d | 6 (9.1) |
| 60 d | 11 (16.7) |
| Characteristics . | N (%) . |
|---|---|
| Total patients | 66 (100) |
| Age, median (range) (y) | 54.9 (23-59) |
| Gender | |
| Male | 37 (56) |
| Female | 29 (44) |
| AML subtype | |
| AML-MRC | 52 (79) |
| Morphology | 17 (26) |
| Cytogenetics | 11 (17) |
| Prior Dx MDS | 23 (35) |
| Prior Dx CMML | 1 (2) |
| Therapy-related AML | 14 (21) |
| Previous HMA treatment for MDS | |
| Yes | 16 (24) |
| No | 50 (76) |
| Baseline mutations of interest | |
| TP53 | 19 (30) |
| RUNX1 | 14 (22) |
| DNMT3A | 11 (17) |
| NRAS | 11 (17) |
| ASXL1 | 7 (11) |
| NPM1 | 7 (11) |
| FLT3 ITD | 5 (8) |
| IDH1 | 5 (8) |
| IDH2 | 3 (5) |
| Cytogenetics | |
| Complex | 30 (46) |
| Monosomal | 17 (26) |
| Normal | 10 (15) |
| Del 7 | 7 (11) |
| Trisomy 8 | 4 (16) |
| 17p | 3 (5) |
| Minus 5q | 2 (3) |
| Outcomes (out of 62 pts) | |
| CR | 19 (30.6) |
| CRi | 8 (12.9) |
| CR/CRi | 27 (43.5) |
| MLFS | 2 (3.2) |
| NR | 33 (53) |
| Mortality | |
| 30 d | 6 (9.1) |
| 60 d | 11 (16.7) |
Dx, diagnosis; pts, patients; NR, nonresponder.